Concenter BioPharma
Drugs for the Treatment and Prevention of Type 2 Diabetes
Company Overview
Snapshot
Founded in January 2014 by Dror Chevion and Prof. Mordechai (Mottie) Chevion, Concenter BioPharma operates with 1–10 employees. The company has raised $3.18 million across three funding rounds from two investors. In January 2026, Concenter BioPharma secured funding from ExitValley.
Business overview
Concenter BioPharma is a Health Tech & Life Sciences company focused on developing drugs for the treatment and prevention of type 2 diabetes. The company's core technology involves a platform of nonsteroidal chemical complexes, derived from clinically approved components, which act as anti-inflammatory, iron-chelating, and antibiotic agents. These new chemical entities are designed to address the causes and symptoms of multiple indications, serving the pharmaceutical and biotechnology markets globally, with a focus on the United States, Asia, and Europe.
Strategic signal
In January 2020, Concenter BioPharma's drug development efforts for type 2 diabetes were highlighted, signaling potential for a novel therapeutic approach. This indicates the company's ongoing commitment to addressing the root causes of diabetes, which could be a significant development for the pharmaceutical industry and investors seeking innovative solutions in chronic disease management.
Log in to access full profile ›Company Intelligence Q&A
- When was Concenter BioPharma founded?
- Concenter BioPharma was founded in January 2014 by Dror Chevion and Prof. Mordechai (Mottie) Chevion.
- What is Concenter BioPharma's primary focus?
- Concenter BioPharma focuses on developing drugs for the treatment and prevention of type 2 diabetes, utilizing a platform of nonsteroidal chemical complexes.
- How much capital has Concenter BioPharma raised to date?
- Concenter BioPharma has raised a total of $3.18 million across three funding rounds.
- What was a key news highlight for Concenter BioPharma in January 2020?
- In January 2020, news highlighted Concenter BioPharma's development of a pill that could address the root cause of diabetes, indicating progress in their drug development efforts.